+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
296 locations
I

Actively Recruiting

Researchers are studying Developmental and Epileptic Encephalopathies DEEs caused by genetic factors, which are complex neurodevelopmental disorders marked by intellectual disability and drug-resistant epilepsy. The study focuses on identifying and combining multiple biological markers biomarkers from routine clinical tests to improve diagnosis, prognosis, and help develop future targeted treatments. This international, observational project includes about 200 participants up to 55 years old, with both DEE patients and healthy controls. Participants do not receive experimental treatments as this is an observational study. Instead, biological samples such as blood, urine, stool, and cerebrospinal fluid if available from necessary medical procedures are collected for metabolomic, extracellular vesicle, and gut microbiota analysis. Resting-state EEG recordings are also analyzed to study brain electrical activity. Data on demographics, genetics, seizures, neurological and gastrointestinal symptoms are gathered through clinical records and questionnaires. Participants contribute routine clinical samples and information without additional invasive procedures. Researchers measure neurophysiological and metabolomic profiles, gut microbiota, and extracellular vesicles once at the initial visit. The study aims to minimize burden and risk by using existing clinical data and samples. Strict privacy protections are in place, and the research supports future therapeutic development. The study runs until December 2028, with primary outcome data expected by December 2025.

Age: 0Years - 55YearsAll Genders
14 locations
L

Actively Recruiting

Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.

Age: 55Years - 90YearsAll GendersPhase 3
432 locations